Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Flovent HFA pressurized metered dose inhaler
Fluticasone propionate pressurized metered dose inhaler · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Investigational Test Product | EXPERIMENTAL | Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation |
| Reference Listed Drug | ACTIVE_COMPARATOR | Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation |
| Placebo | PLACEBO_COMPARATOR | Placebo pressurized metered dose inhaler, no active content |
| Name | Type | Description |
|---|---|---|
| Fluticasone propionate pressurized metered dose inhaler | DRUG | 110 mcg per actuation |
| Flovent HFA pressurized metered dose inhaler | DRUG | 110 mcg per actuation |
| Placebo pressurized metered dose inhaler | DRUG | no active content |
Inclusion Criteria: 1. Adult ≥18 and ≤75 years of age male or female subjects of non-child bearing potential or of child bearing potential committing to consistent and correct use of an acceptable method of birth control. 2. Body mass index (BMI) ≥18 and ≤45. 3. Diagnosis of asthma, as defined by t...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Fluticasone propionate pressurized metered dose inhaler is an investigational inhaled asthma therapy developed by Teva Pharmaceutical Industries Limited. It delivers fluticasone propionate, a small molecule, at a 110 mcg dose. It is being studied as a therapeutic equivalent to Flovent HFA 110 mcg for treating asthma in adults.
Fluticasone propionate pressurized metered dose inhaler is being developed for the treatment of asthma. The Phase 3 program evaluated it in adults 18 years and older with asthma in the United States. It is designed as a pressurized metered dose inhaler delivering 110 mcg of fluticasone propionate per actuation.
Teva Pharmaceutical Industries Limited is developing fluticasone propionate pressurized metered dose inhaler. Teva trades on the New York Stock Exchange under the ticker TEVA. The company sponsored the Phase 3 therapeutic equivalence study of the 110 mcg inhaler against Flovent HFA 110 mcg.
Fluticasone propionate pressurized metered dose inhaler has completed a Phase 3 clinical trial. It is an investigational product and is not described as approved. The Phase 3 study, NCT03879837, has been completed and enrolled 1,902 participants.
Fluticasone propionate pressurized metered dose inhaler was studied in one Phase 3 trial, NCT03879837, titled Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg. The trial was completed, enrolled 1,902 adults with asthma in the United States, and was randomized, double blind, and placebo controlled.